Latest news with #AUR87A
Yahoo
25-03-2025
- Health
- Yahoo
Elypta's urine test identifies 90% of recurrent kidney cancer cases
Swedish cancer diagnostic company Elypta's urine test has been able to accurately identify 90% of patients with recurrent kidney cancer. The business announced the intermediary results from its prospective multi-centre trial designed to determine if urine-collected glycosaminoglycans (GAGomes) can be used for the early detection of cancer recurrence. Specifically, following curative surgery in patients with high or intermediate risk of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. Elypta announced the early results as part of the 2025 European Association of Urology Congress, taking place in Madrid, Spain. The trial was co-funded by the European Union's Horizon 2020 research and innovation programme and took place at 29 international locations. The trial featured an adaptive design with primary endpoint analysis carried out after 30 events or recurrences had been reached. The company says the results underline the ability of clinicians to pivot away from the use of radiological examination for post-treatment patients, instead pushing for the use of patients' submitted urine samples as routine observation. Now, Elypta claims that the study's second patient cohort is nearing final recruitment, with validation results expected later this year. Elypta chief medical officer Volker Liebenberg said: 'A urine test can offer a less invasive and more comfortable alternative for post-operative monitoring, potentially transforming kidney cancer follow-up care.' Commenting on results from the AUR87A trial, Elypta CEO Karl Bergman said: 'These findings show the potentially transformative impact a urine-based test may have in the surveillance of recurrent disease for kidney cancer patients.' Elsewhere in the field of cancer diagnostics, Proscia has secured $50m to advance its AI-driven digital pathology platform designed to allow clinicians to interpret whole slide images. "Elypta's urine test identifies 90% of recurrent kidney cancer cases" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
25-03-2025
- Health
- Yahoo
Urine test could help spot recurring kidney cancer, researchers say
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
The Independent
24-03-2025
- Health
- The Independent
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
Yahoo
24-03-2025
- Health
- Yahoo
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
